Bipolar Disorder

In an interview, Jacob Ballon, MD, MPH, discusses the significance of his team’s study which found olanzapine and samidorphan was well-tolerable for up to 4 years of treatment for schizophrenia and bipolar disorder treatment.

A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.

Mothers with mood disorders—either bipolar disorder, major depressive disorder— or schizophrenia/ schizoaffective disorder are not associated with their offspring’s risk for type 1 diabetes. Results suggest mothers with bipolar disorder tend to develop type 1 diabetes, but data is not clinically significant.

A large systematic review assessing more than 60 drugs for bipolar depression shows only a handful were statistically signifcantly better than placebo per depressive symptom outcomes.

The findings underscore the importance of considering both the severity of BPD features and changes in depressive symptoms when assessing risk of suicide.

A prospective cohort analysis of Denmark residents suggests correlation between cannabis overuse and risk of psychiatric conditions.

The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.

Children definite motor problems were more likely to have psychotic experiences compared to children with no definite motor problems.

A new cross-sectional analysis suggest there are few options available for patients with schizophrenia or a serious mood disorder.

There was a decrease in relapse observed for low-risk participants, but not high-risk individuals.

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs.

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population.

Clinical decision support intervention resulted in a rate of change in total modifiable CV risk that was 4% lower among intervention patients compared to control.

The treatment is approved as either a monotherapy or an adjunctive therapy with either lithium or valproate.

Circadian disruption presented across a variety of high-risk, prodromal, and syndromic psychiatric disorders.

Higher depressive and manic (symptoms were associated with lower GAF, most strongly among the older participants.

Severe mental disorders had the highest odds ratios for the risk of mortality.

Lamotrigine is currently being used as a maintenance therapy for bipolar disorder.

New data show significant therapeutic effects of dextraomethadone treatment in MDD patients below the median percentage of life-years from diagnosis.

A new study from APA 2021 finds algorithm use can reduce clinical misdiagnosis of bipolar disorder as other mood disorders, including major depressive disorder.

A higher percentage of patients suffering from a severe mental disorder such as schizophrenia or bipolar disorder, died from a COVID-19 infection than the control group.

Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.

Both monotherapy and combination of the unique regimen was shown to improve manic and depressive status at 12 weeks.

Repeated Transcranial Magnetic Stimulation shows more efficacy treating bipolar disorder than schizophrenia.

The agency did not find any efficacy or safety issues regarding the potential treatment for adults with schizophrenia or bipolar I disorder.

Patients with bipolar depression have struggled during the COVID-19 pandemic.

Association with familial history found in hospitalizations, suicide attempts, and an earlier onset of symptoms.

There were no significant differences observed in mood episodes for bipolar patients in either AISR therapy or standard treatment.

An analysis of 20-year outpatient prescribing trends show the drug class is being favored over mood stabilizers.